ArticleJournal of nanomedicine & nanotechnology2016
Targeted Theranostic Approach for Glioma Using Dendrimer-Based Curcumin Nanoparticle.
Article in Journal of nanomedicine & nanotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Understanding DMG: current treatment options and prospective solutions using nanoparticles.Drug delivery and translational research · 2026Review
- Receptor-Assisted Nanotherapeutics for Overcoming the Blood-Brain Barrier.Molecular neurobiology · 2024Review
- Review
- Multifunctional Nanocarriers for Alzheimer's Disease: Befriending the Barriers.Molecular neurobiology · 2024Review
- Nano-based drug delivery systems for active ingredients from traditional Chinese medicine: Harnessing the power of nanotechnology.Frontiers in pharmacology · 2024Review
- Review
- Bioaccessibility and Bioavailability of Diet Polyphenols and Their Modulation of Gut Microbiota.International journal of molecular sciences · 2023Review
- Dendrimer: An update on recent developments and future opportunities for the brain tumors diagnosis and treatment.Frontiers in pharmacology · 2023Review
- Focused Delivery of Chemotherapy to Augment Surgical Management of Brain Tumors.Current oncology (Toronto, Ont.) · 2022Review
- Improving Curcumin Bioavailability: Current Strategies and Future Perspectives.Pharmaceutics · 2021Review
- Dendrimer-Based Nanomedicine (Paramagnetic Nanoparticle, Nanocombretastatin, Nanocurcumin) for Glioblastoma Multiforme Imaging and Therapy.Novel approaches in cancer study · 2021Article
- Curcumin's Nanomedicine Formulations for Therapeutic Application in Neurological Diseases.Journal of clinical medicine · 2020Review
- Nano-Therapies for Glioblastoma Treatment.Cancers · 2020Review
- Enhancing Curcumin Oral Bioavailability Through Nanoformulations.European journal of drug metabolism and pharmacokinetics · 2019Review
- Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends.Drug delivery and translational research · 2018Review
- Use of Polyamidoamine Dendrimers in Brain Diseases.Molecules (Basel, Switzerland) · 2018Review
- Brain Delivery of Multifunctional Dendrimer Protein Bioconjugates.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2018Article
- MRI Monitoring of Cerebral Blood Flow after the Delivery of Nanocombretastatin across the Blood Brain Tumor Barrier.Journal of nanomedicine & nanotechnology · 2018Article
- Targeting Triple Negative Breast Cancer with a Small-sized Paramagnetic Nanoparticle.Journal of nanomedicine & nanotechnology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
The delivery of anti-cancer agents to brain tumors represent a challenge because the blood-brain tumor barrier (BBTB) effectively limits the delivery of many agents. A new generation 3 (G3) dendrimer-based curcumin (Curc) conjugate was synthesized. The synthesized G3-Curc conjugate demonstrated full solubility in aqueous media. The in vitro study revealed that G3-Curc nanoparticles were internalized into glioma U-251 cells. Systemic delivery of G3-Curc conjugate led to preferentially accumulation in an orthotopic preclinical glioma model minimizing systemic toxic effect. Multicolor microscopy images of the tumor tissue showed that G3-Curc particles were internalized inside tumor cells selectively and further localized within nuclei. Enhanced bioavailability of G3-Curc conjugate was also observed with improved therapeutic efficacy against different cancers cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.